Reuters

05 Jun 2026, 23:31 UTC · 4h ago

Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

Read original · https://www.reuters.com/business/healthcare-pharmaceuticals/roche-obesity-drug-helps-patients-shed-227-weight-mid-stage-trial-2026-06-05/

Top 2 movers · tap to explore

Story key points

2 claims · impact-rated

What matters in this story

1
Roche's experimental obesity drug showed a 22.7% average weight loss in a mid-stage trial. — Strong efficacy data in the high-growth GLP-1 market increases Roche's valuation and competitiveness against incumbents.
+0.60
2
Over 25% of patients receiving the highest dose of the drug achieved weight loss of at least 30%. — The ability to reach 30% weight loss suggests the drug may be a 'best-in-class' contender, potentially capturing significant market share.
+0.40

Ticker attribution

Model heads

Sentiment in this article

ROG+0.80
Positive mid-stage trial results for an experimental obesity drug showing significant weight loss.

6 related stories

Reuters
7h ago
Zealand touts promising tolerability data for obesity drug in mid-stage study
- clinical trials
- obesity drug
- pharma
Read

Roche obesity drug helps patients shed 22.7% of weight in mid-stage t… · News Impact Screener

Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

What matters in this story

Sentiment in this article

Zealand touts promising tolerability data for obesity drug in mid-stage study

Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

What matters in this story

Sentiment in this article

Zealand touts promising tolerability data for obesity drug in mid-stage study

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead

Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

What matters in this story

Sentiment in this article

Next reads from the same story arc

Zealand touts promising tolerability data for obesity drug in mid-stage study

Roche obesity drug helps patients shed 22.7% of weight in mid-stage trial

What matters in this story

Sentiment in this article

Next reads from the same story arc

Zealand touts promising tolerability data for obesity drug in mid-stage study

Relationships in this article

You’re reading about it. Someone else is already positioned.

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

NatureU® Now Has Three Clinical Studies Publicly Registered on ClinicalTrials.gov as 56-Day PQQ Skin-Aging Study (NCT07571629) Joins Two Previously Published Peer-Reviewed Trials

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC

Avalyn Pharma Outlines Inhaled Fibrosis Push After IPO, With Pivotal Data Ahead